GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

atrasentan   Click here for help

GtoPdb Ligand ID: 3487

Synonyms: A-127722 | A-147627 | ABT-627
Approved drug
atrasentan is an approved drug
Compound class: Synthetic organic
Comment: Atrasentan (ABT-627) is an orally available, nonpeptide endothelin receptor antagonist. The stereochemistry represented here matches that defined in the INN record for atrasentan.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 13
Topological polar surface area 88.54
Molecular weight 510.27
XLogP 4.23
No. Lipinski's rules broken 1

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES CCCCN(C(=O)CN1CC(C(C1c1ccc(cc1)OC)C(=O)O)c1ccc2c(c1)OCO2)CCCC
Isomeric SMILES CCCCN(C(=O)CN1C[C@@H]([C@H]([C@@H]1c1ccc(cc1)OC)C(=O)O)c1ccc2c(c1)OCO2)CCCC
InChI InChI=1S/C29H38N2O6/c1-4-6-14-30(15-7-5-2)26(32)18-31-17-23(21-10-13-24-25(16-21)37-19-36-24)27(29(33)34)28(31)20-8-11-22(35-3)12-9-20/h8-13,16,23,27-28H,4-7,14-15,17-19H2,1-3H3,(H,33,34)/t23-,27-,28+/m1/s1
InChI Key MOTJMGVDPWRKOC-QPVYNBJUSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
Atrasentan was assessed in a Phase 1/II clinical trial as a potential anti-cancer treatment (in combination with paclitaxel and carboplatin) but the compound did not show improved efficacy compared to chemotherapy alone in NSCLC [1]. Phase 3 evaluation in prostate cancer also failed. Development of atrasentan for diabetic nephropathy was continued and reached Phase 3 [9,11]. Most recently, Chinook Therapeutics evaluated atrasentan as a treatment for kidney diseases such as IgA nephropathy and Alport syndrome [4,10,12]. The first FDA approval was issued in April 2025, with atrasentan (Vanrafia®) indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Atrasentan is an antagonist of the endothelin A (ETA) receptor. The molecular machanism underlying anti-cancer effects are attributed to atrasentan's ability to inhibit endothelin-induced cell proliferation [7]. This effect is particularly relevant in prostate cancer where endothelin levels are elevated [5]. As a treatment for diabetic nephropathy, atrasentan is reported to reduce renal injury via an anti-inflammatory mechanism involving inhibition of superoxide production [8].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01858532 Study Of Diabetic Nephropathy With Atrasentan Phase 3 Interventional AbbVie The SONAR study 3
NCT00036556 Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer Phase 3 Interventional Abbott
NCT04573478 Atrasentan in Patients With IgA Nephropathy Phase 3 Interventional Chinook Therapeutics, Inc. 2
NCT04573920 Atrasentan in Patients With Proteinuric Glomerular Diseases Phase 2 Interventional Chinook Therapeutics, Inc.